Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 182

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 182
---
.8 months. Amdizalisib showed an acceptable safety profile and promising anti-tumor activity in relapsed/refractory lymphoma.

Table of Contents

15. Immunology Collaboration with Inmagene

We have a strategic partnership with Inmagene to develop two novel drug candidates (IMG-004 and IMG-007) discovered by us for the potential treatment of multiple immunological diseases, with funding provided by Inmagene. We received shares representing approximately 7.5% of the shares in Inmagene (fully diluted) in July 2024, as consideration for Inmagene’s exclusive license to further develop, manufacture and commercialize these two drug candidates worldwide. On December 23, 2024, Inmagene and Ikena Oncology, Inc. (Nasdaq: IKNA, “ Ikena,”) announced that they had signed a merger agreement which the parties expect to close in mid-2025, subject to closing conditions. Following closing, we will have an interest in the Nasdaq-listed merged company. For more details on the collaboration arrangement, please see “ - Our Collaborations - Inmagene.”

  Treatment                    Patient Focus                                            Sites             Phase      Status/Plan                               NCT #        
  IMG-007 (OX40 antibody)      Adults with moderate-to-severe atopic dermatitis         U. S. Canada      IIa        Full results IIb planned for Q1 2025      NCT05984784  
  IMG-007 (OX40 antibody)      Alopecia areata with 50% or greater scalp hair loss      U. S. Canada      IIa        Fully enrolled; results pending           NCT06060977  
  IMG-004 (BTK inhibitor)      Adult healthy volunteers                                 U. S.             I          Single ascending dose completed           NCT05349097  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

IMG-007, a novel antagonistic monoclonal antibody targeting the OX40 receptor with silenced antibody-dependent cell-mediated cytotoxicity function. OX40 is a costimulatory receptor, a member of the tumor necrosis factor receptor superfamily expressed predominantly on activated T cells. One Phase IIa study has announced results and one Phase IIa study has completed recruitment.

IMG-007 in atopic dermatitis (NCT05984784) - This trial evaluates the safety, pharmacokinetics and efficacy of IMG-007 in adult